Renin Trajectories and Outcome in Stable Heart Failure with Reduced Ejection Fraction (HFrEF) on Contemporary Therapy: A Monocentric Study from an Austrian Tertiary Hospital Outpatient Clinic.
Journal
Journal of the renin-angiotensin-aldosterone system : JRAAS
ISSN: 1752-8976
Titre abrégé: J Renin Angiotensin Aldosterone Syst
Pays: England
ID NLM: 100971636
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
08
2023
revised:
12
10
2023
accepted:
14
10
2023
medline:
10
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
The renin-angiotensin system (RAS) is the main target of neurohumoral therapy in heart failure with reduced ejection fraction (HFrEF) effectively reducing mortality. Reasonably, renin might serve as a biomarker for risk prediction and therapy response. Renin indeed bears some additional value to clinical risk models, albeit the effect is not pronounced. Whether assessing renin trajectories can overcome the weaknesses of single renin measurements has not been reported. A total of 505 patients with stable HFrEF were enrolled prospectively and followed through routine clinical visits. Active plasma renin concentration was documented up to 5 years. Changes in renin were analyzed throughout the disease course, and survival was compared for different renin trajectories within the first year. Baseline renin levels were not related to all-cause mortality (crude HR for an increase of 100 Intriguingly, renin is not a good biomarker to indicate prognosis in HF, while renin trajectories over a 1-year period do not have an additional value. Rapid physiologic plasma renin variations, but also opposing effects of angiotensinogen-derived metabolites under presence of RAS blockade, might obscure the predictive ability of renin.
Identifiants
pubmed: 37941680
doi: 10.1155/2023/8883145
pmc: PMC10630017
doi:
Substances chimiques
Renin
EC 3.4.23.15
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8883145Informations de copyright
Copyright © 2023 Emilie Han et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Eur J Heart Fail. 2018 Apr;20(4):677-686
pubmed: 29143416
J Renin Angiotensin Aldosterone Syst. 2010 Mar;11(1):19-31
pubmed: 19861349
Am Heart J. 2011 Oct;162(4):585-96
pubmed: 21982648
N Engl J Med. 1987 Jun 4;316(23):1429-35
pubmed: 2883575
Circulation. 2002 Aug 27;106(9):1055-7
pubmed: 12196328
J Intern Med. 2008 Sep;264(3):224-36
pubmed: 18793332
N Engl J Med. 2001 Dec 6;345(23):1667-75
pubmed: 11759645
Int J Cardiol. 2021 Dec 15;345:54-60
pubmed: 34728260
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Clin Chem. 2018 Mar;64(3):597-608
pubmed: 29138270
Circ J. 2007 Jun;71(6):915-21
pubmed: 17526990
J Intern Med. 2001 Feb;249(2):167-72
pubmed: 11240846
ESC Heart Fail. 2020 Jun;7(3):953-963
pubmed: 32167681
JACC Heart Fail. 2022 Jan;10(1):1-11
pubmed: 34969491
Eur Heart J. 2011 Sep;32(17):2135-42
pubmed: 21415069
Eur J Heart Fail. 2017 May;19(5):627-634
pubmed: 28247565
Circ Res. 2016 Apr 15;118(8):1313-26
pubmed: 27081112
J Am Coll Cardiol. 1992 Jul;20(1):248-54
pubmed: 1351488
J Card Fail. 2010 Dec;16(12):964-70
pubmed: 21111986
JAMA. 2013 Mar 20;309(11):1125-35
pubmed: 23478743
Endocr J. 2020 Nov 28;67(11):1127-1138
pubmed: 32612066
Heart. 2007 Sep;93(9):1026-33
pubmed: 17488768
J Clin Hypertens (Greenwich). 2004 Apr;6(4):175-83; quiz 184-5
pubmed: 15073471
J Neurol Sci. 2014 Nov 15;346(1-2):333-4
pubmed: 25145993
Eur Heart J. 2004 Feb;25(4):292-9
pubmed: 14984917
Heart Fail Rev. 2022 Mar;27(2):625-643
pubmed: 33852110
Circ J. 2015;79(6):1307-14
pubmed: 25753468